Financials Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Delayed NSE India S.E. 10:53:28 2025-02-06 pm EST 5-day change 1st Jan Change
1,004.85 INR -0.33% Intraday chart for Zydus Lifesciences Limited +3.43% +3.28%

Projected Income Statement: Zydus Lifesciences Limited

Forecast Balance Sheet: Zydus Lifesciences Limited

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 56,328 23,588 30,891 5,901 -3,365 -25,013 -60,576 -88,785
Change - -58.12% 30.96% -80.9% -157.02% -843.33% -342.18% -246.57%
Announcement Date 6/19/20 5/27/21 5/20/22 5/18/23 5/17/24 - - -
1INR in Million
Estimates

Cash Flow Forecast: Zydus Lifesciences Limited

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
CAPEX 1 9,041 8,540 12,026 10,309 9,066 12,254 11,599 11,985
Change - -5.54% 40.82% -14.28% -12.06% 35.17% -5.34% 3.33%
Free Cash Flow (FCF) 1 16,013 24,390 9,015 16,579 23,213 33,150 40,140 39,591
Change - 52.31% -63.04% 83.9% 40.01% 42.81% 21.08% -1.37%
Announcement Date 6/19/20 5/27/21 5/20/22 5/18/23 5/17/24 - - -
1INR in Million
Estimates

Forecast Financial Ratios: Zydus Lifesciences Limited

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027

Profitability

        
EBITDA Margin (%) 19.22% 22.12% 21.88% 20.74% 27.13% 29.65% 27.93% 25.47%
EBIT Margin (%) 14.33% 17.32% 17.21% 18.2% 23.22% 25.85% 24.33% 21.25%
EBT Margin (%) 10.49% 15.13% 18.59% 15.02% 24.6% 26.42% 25.09% 22.78%
Net margin (%) 8.26% 14.13% 29.4% 11.37% 19.74% 20.43% 18.97% 17.02%
FCF margin (%) 11.23% 16.15% 5.91% 9.62% 11.88% 14.43% 16.38% 15.45%
FCF / Net Income (%) 136.1% 114.31% 20.09% 84.57% 60.15% 70.62% 86.33% 90.74%

Profitability

        
ROA 4.99% 8.97% 8.32% 7.32% 13.98% 15.65% 13.54% 11.49%
ROE 11.33% 18.26% 14.33% 11.36% 20.61% 20.65% 17.62% 14.65%

Financial Health

        
Leverage (Debt/EBITDA) 2.06x 0.71x 0.92x 0.17x - - - -
Debt / Free cash flow 3.52x 0.97x 3.43x 0.36x - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 6.34% 5.65% 7.88% 5.98% 4.64% 5.33% 4.73% 4.68%
CAPEX / EBITDA (%) 33.01% 25.56% 36% 28.83% 17.1% 17.99% 16.94% 18.36%
CAPEX / FCF (%) 56.46% 35.01% 133.4% 62.18% 39.06% 36.97% 28.9% 30.27%

Items per share

        
Cash flow per share 1 24.47 32.16 20.55 26.47 31.9 50.06 51.27 50.26
Change - 31.46% -36.12% 28.83% 20.5% 56.92% 2.44% -1.98%
Dividend per Share 1 3.5 3.5 2.5 6 3 5.747 6.456 6.666
Change - 0% -28.57% 140% -50% 91.56% 12.33% 3.25%
Book Value Per Share 1 101.3 126.9 166 173.1 197.1 238 277.3 316.9
Change - 25.22% 30.84% 4.26% 13.88% 20.72% 16.54% 14.28%
EPS 1 11.49 20.84 43.83 19.3 38.14 46.54 46.12 43.39
Change - 81.38% 110.32% -55.97% 97.62% 22.01% -0.9% -5.91%
Nbr of stocks (in thousands) 1,023,743 1,023,743 1,023,743 1,012,204 1,006,234 1,006,234 1,006,234 1,006,234
Announcement Date 6/19/20 5/27/21 5/20/22 5/18/23 5/17/24 - - -
1INR
Estimates
2025 *2026 *
P/E ratio 21.7x 21.9x
PBR 4.24x 3.64x
EV / Sales 4.31x 3.89x
Yield 0.57% 0.64%
More valuation ratios * Estimated data

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Trading Rating
Investor Rating
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
31
Last Close Price
1,008.20INR
Average target price
1,069.45INR
Spread / Average Target
+6.08%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ZYDUSLIFE Stock
  4. Financials Zydus Lifesciences Limited